Title
Dual RNA-seq identifies human mucosal immunity protein Mucin-13 as a hallmark of Plasmodium exoerythrocytic infection
Date Issued
01 December 2019
Access level
open access
Resource Type
journal article
Author(s)
LaMonte G.M.
Orjuela-Sanchez P.
Wang L.T.
Li S.
Swann J.
Cowell A.N.
Zou B.Y.
Abdel-Haleem Mohamed A.M.
Villa Galarce Z.H.
Lewis N.
Winzeler E.A.
Publisher(s)
Nature Publishing Group
Abstract
The exoerythrocytic stage of Plasmodium infection is a critical window for prophylactic intervention. Using genome-wide dual RNA sequencing of flow-sorted infected and uninfected hepatoma cells we show that the human mucosal immunity gene, mucin-13 (MUC13), is strongly upregulated during Plasmodium exoerythrocytic hepatic-stage infection. We confirm MUC13 transcript increases in hepatoma cell lines and primary hepatocytes. In immunofluorescence assays, host MUC13 protein expression distinguishes infected cells from adjacent uninfected cells and shows similar colocalization with parasite biomarkers such as UIS4 and HSP70. We further show that localization patterns are species independent, marking both P. berghei and P. vivax infected cells, and that MUC13 can be used to identify compounds that inhibit parasite replication in hepatocytes. This data provides insights into host-parasite interactions in Plasmodium infection, and demonstrates that a component of host mucosal immunity is reprogrammed during the progression of infection.
Volume
10
Issue
1
Number
488
Language
English
OCDE Knowledge area
Bioquímica, Biología molecular Parasitología
Scopus EID
2-s2.0-85060927700
PubMed ID
Source
Nature Communications
ISSN of the container
20411723
Sponsor(s)
We thank the members of the Winzeler and Lewis labs for advice and critical reading of the manuscript. In addition, we thank Medicines for Malaria Venture for all of their support of the insectary in Peru. We would also like to thank the UCSD Institute for Genomic Medicine Sequencing Core Facility and the UCSD Human Embryonic Stem Cell Flow Cytometry Core Facility for their technical support. G.L. is supported by an A. P. Giannini Post-Doctoral Fellowship. E.A.W. is supported by grants from the NIH (5R01AI090141 and R01AI103058). N.E.L. and S.L. received funding from the NIGMS (R35 GM119850) and the Novo Nordisk Foundation through the Center for Biosus-tainability at the Technical University of Denmark (NNF10CC1016517). The P. vivax work was supported by grants to J.M.V. from the NIH (D43TW007120 and U19AI089681). A.N.C. received support from a NIH T32 AI 007036 training grant. National Institutes of Health 5R01AI090141, R01AI103058 NIH National Institute of General Medical Sciences R35 GM119850 NIGMS Fogarty International Center D43TW009343 FIC Danmarks Tekniske Universitet D43TW007120, NNF10CC1016517, T32 AI 007036, U19AI089681 DTU Novo Nordisk Fonden NNF
Sources of information: Directorio de Producción Científica Scopus